Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.54 |
| ▸ | PLK1 | P53350 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | PRKACG | P22612 | 1/20 | 0.43 |
| ▸ | PRKACB | P22694 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12479702 | 0.87 | CDC25A (0.51) | CDC25APLK1ALDH1A1LMNATDP1 | |
| SCHEMBL31432746 | 0.87 | CDC25A (0.55) | CDC25APLK1ALDH1A1LMNAMCL1 | |
| SCHEMBL10442568 | 0.83 | OXER1 (0.56) | PLK1MCL1OXER1KDM4E | |
| SCHEMBL12368671 | 0.83 | KMT2A (0.58) | CDC25APLK1ALDH1A1LMNAMCL1 | |
| SCHEMBL5814849 | 0.83 | ALDH1A1 (0.44) | CDC25APLK1ALDH1A1L3MBTL1OXER1 | |
| SCHEMBL23318400 | 0.82 | CDC25A (0.50) | CDC25APLK1ALDH1A1LMNATDP1 | |
| SCHEMBL7618314 | 0.81 | CDC25A (0.55) | CDC25APLK1ALDH1A1LMNATDP1 | |
| SCHEMBL1226938 | 0.81 | L3MBTL1 (0.71) | CDC25AALDH1A1LMNATDP1L3MBTL1 | |
| SCHEMBL5742862 | 0.80 | OXER1 (0.41) | CDC25AALDH1A1L3MBTL1OXER1AKR1C3 | |
| SCHEMBL5304010 | 0.80 | HTR2A (0.57) | ALDH1A1OXER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230524-A1 | SUBSTITUTED 2-(5-HYDROXY-2-METHYL-1H-INDOLE-3-YL)ACETIC ACIDS AND ETHERS THEREOF AND THE USE OF SAME TO TREAT VIRAL DISEASES | ALLA CHEM, LLC. | 2011-09-22 | — | — | US | claimed |
| US-8481587-B2 | Substituted 2-(5-hydroxy-2-methyl-1H-indole-3-yl)acetic acids and ethers thereof and the use of same to treat viral diseases | IVASHCHENKO ANDREY ALEXANDROVICH (RU) | 2013-07-09 | — | — | US | disclosed |
| US-20110230524-A1 | SUBSTITUTED 2-(5-HYDROXY-2-METHYL-1H-INDOLE-3-YL)ACETIC ACIDS AND ETHERS THEREOF AND THE USE OF SAME TO TREAT VIRAL DISEASES | ALLA CHEM, LLC. | 2011-09-22 | — | — | US | disclosed |
| EP-1098895-B1 | METHOD FOR PREPARING LINTITRIPT POTASSIUM SALT | SANOFI SYNTHELABO (FR) | 2002-06-05 | — | — | EP | disclosed |
| US-6365748-B1 | BY TREATING 2-((4-(2-CHLOROPHENYL)-2-THIAZOLYL)CARBAMOYL) INDOLE-1-ACETIC ACID OR ITS ESTERS WITH POTASSIUM CARBONATE IN A TWO PHASE SOLVENT SYSTEM,OF A MIXTURE OF WATER AND A SLIGHTLY IMMISCIBIBLE SOLVENT; INJECTIBLE CHOLECYSTOKININ | SANDOFI-SYNTHELABO (FR) | 2002-04-02 | — | — | US | disclosed |
| EP-1098895-A1 | METHOD FOR PREPARING LINTITRIPT POTASSIUM SALT | SANOFI-SYNTHELABO (FR) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000005233-A1 | METHOD FOR PREPARING LINTITRIPT POTASSIUM SALT | SANOFI-SYNTHELABO (FR) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230524-A1 | SUBSTITUTED 2-(5-HYDROXY-2-METHYL-1H-INDOLE-3-YL)ACETIC ACIDS AND ETHERS THEREOF AND THE USE OF SAME TO TREAT VIRAL DISEASES | IDO1, TPH1, FOXM1 | CDC25A 691/4885PLK1 4604/4885ALDH1A1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.